AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25996764 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal placebo
Number of subjects: 32
Study 22840893 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information with circular path
Number of subjects: 40
Study 22840893 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information with figure-eight path
Number of subjects: 40
Study 22840893 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive information with circular path
Number of subjects: 40
Study 22840893 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive information with figure-eight path
Number of subjects: 40
Study 22840893 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information
Number of subjects: 40
Study 22840893 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive information
Number of subjects: 40
Study 21823415 — intervention group
Group type: EXPERIMENTAL
Intervention: Back‐shu point needling
Number of subjects: 90
Study 21823415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Back‐shu point needling and trunk exercise
Number of subjects: 90
Study 21823415 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 90
Study 19243724 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage therapy (MLDT)
Number of subjects: 50
Study 19243724 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue massage (CTM)
Number of subjects: 50
Study 16045516 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal education
Number of subjects: 1312
Study 16045516 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional single educational group session supervised by a lactation specialist
Number of subjects: 1312
Study 11847955 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 4800000
Study 10515308 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine (low-dose group)
Number of subjects: 9
Study 10515308 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine (high-dose group)
Number of subjects: 9
Study 10515308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7733124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg/d for the first month; thereafter, 400 mg/d for 2 weeks of every 3-month period), elemental calcium (1 g/d), and ergocalciferol (0.5 mg/wk)
Number of subjects: 26
Study 7733124 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplements only (1 g/d)
Number of subjects: 26
Study 1914367 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sibutramine
Number of subjects: 55
Study 1914367 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sibutramine
Number of subjects: 55
Study 1914367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7017991 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/day of chenodeoxycholic acid (CDCA) for 4 months, followed by an additional 4 months for those showing a 25% or more decrease in stone size.
Number of subjects: 13
Study 7017991 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months, followed by CDCA for those who initially received placebo.
Number of subjects: 13
Study 31912632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg, subcutaneous, biweekly for 6 weeks)
Number of subjects: 12
Study 31912632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30321476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU/day)
Number of subjects: 453
Study 30321476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study 28382813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical training (APT) program, held twice a week for 16 weeks
Number of subjects: 54
Study 28382813 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 54
Study 28382813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical training (APT) program
Number of subjects: 54
Study 25500940 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetist-directed fluid therapy
Number of subjects: 130
Study 25500940 — intervention group
Group type: COMPARATOR
Intervention: Pulse-contour-guided fluid optimization strategy using colloid (Gelofusine) boluses
Number of subjects: 130
Study 25500940 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of four studies
Number of subjects: 130
Study 23336505 — intervention group
Group type: EXPERIMENTAL
Intervention: JZQG (Jiangzhuoqinggan)
Number of subjects: 240
Study 23336505 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 240
Study 21626265 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical source seekers (including physicians)
Number of subjects: 268
Study 21626265 — intervention group
Group type: COMPARATOR
Intervention: Non-seekers
Number of subjects: 268
Study 21626265 — intervention group
Group type: COMPARATOR
Intervention: Non-medical source seekers
Number of subjects: 268
Study 18929355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach to the common femoral artery
Number of subjects: 0
Study 18929355 — intervention group
Group type: COMPARATOR
Intervention: Direct approach to the common femoral artery
Number of subjects: 0
Study 17380681 — intervention group
Group type: EXPERIMENTAL
Intervention: Glide Scope video‐laryngoscope (GSVL)
Number of subjects: 60
Study 17380681 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 60
Study 17380681 — intervention group
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope (FOB)
Number of subjects: 60
Study 15207410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline
Number of subjects: 3000
Study 15207410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 3000
Study 11589865 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (30 microg weekly intramuscular injections)
Number of subjects: 192
Study 11589865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 9532999 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-tip transducers tied together and introduced transcervically into the uterine cavity after delivery of the placenta
Number of subjects: 20
Study 9532999 — intervention group
Group type: COMPARATOR
Intervention: Catheter-tip transducers inserted independently into the same uterine cavity
Number of subjects: 20
Study 7975845 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed leishmanial promastigotes plus BCG
Number of subjects: 208
Study 7975845 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG alone
Number of subjects: 208
Study 7975845 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed leishmanial promastigotes alone
Number of subjects: 208
Study 7975845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 2644335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (ProzacR, Lilly) for 8 weeks
Number of subjects: 76
Study 2644335 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCA)
Number of subjects: 76
Study 1119588 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 94
Study 1119588 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented therapy
Number of subjects: 94
Study 1119588 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 94
Study 1119588 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 94
Study 31913830 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal curriculum including asynchronous video on communication skills and direct patient feedback from the Communication Assessment Tool (CAT)
Number of subjects: 64
Study 31913830 — intervention group
Group type: COMPARATOR
Intervention: Control group received the curriculum at the clerkship's end
Number of subjects: 64
Study 28476553 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarettes (complete switch)
Number of subjects: 105
Study 28476553 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarettes (partial switch)
Number of subjects: 105
Study 28476553 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cessation of tobacco and nicotine products
Number of subjects: 105
Study 28476553 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction (general)
Number of subjects: 105
Study 25391889 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 0
Study 25391889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23533318 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (36 months daily)
Number of subjects: 196
Study 23533318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 196
Study 21831926 — intervention group
Group type: COMPARATOR
Intervention: Stay active care only (group 1)
Number of subjects: 160
Study 21831926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay active care and muscle stretching (group 2)
Number of subjects: 160
Study 21831926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay active care, muscle stretching and manual therapy (group 3)
Number of subjects: 160
Study 21831926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay active care, muscle stretching, manual therapy and steroid injections (group 4)
Number of subjects: 160
Study 18298230 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive‐behavioral therapy
Number of subjects: 113
Study 18298230 — intervention group
Group type: COMPARATOR
Intervention: 12‐step facilitation therapy
Number of subjects: 113
Study 18298230 — intervention group
Group type: EXPERIMENTAL
Intervention: Life stressors
Number of subjects: 113
Study 18298230 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 113
Study 18298230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stress levels
Number of subjects: 113
Study 18298230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress events
Number of subjects: 113
Study 18298230 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of self-efficacy and life stress
Number of subjects: 113
Study 17038946 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester collagen-coated vascular patch
Number of subjects: 315
Study 17038946 — intervention group
Group type: COMPARATOR
Intervention: Direct closure
Number of subjects: 315
Study 12850905 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured aftercare (SA) programme
Number of subjects: 77
Study 12850905 — intervention group
Group type: COMPARATOR
Intervention: Unstructured aftercare (UA) of crisis counselling
Number of subjects: 77
Study 12850905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SA and UA
Number of subjects: 77
Study 12850905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment additional substance use
Number of subjects: 77
Study 12850905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analyses
Number of subjects: 77
Study 10368454 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of rickets
Number of subjects: 27
Study 10368454 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic studies before treatment
Number of subjects: 27
Study 10368454 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic studies after treatment
Number of subjects: 27
Study 10368454 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic studies in group III
Number of subjects: 27
Study 10368454 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy infants)
Number of subjects: 27
Study 8763050 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine (200 mg/d)
Number of subjects: 35
Study 8763050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1988266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg)
Number of subjects: 14
Study 1988266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6645209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide
Number of subjects: 7
Study 6645209 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 7
Study 6645209 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 7
Study 30615587 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice providers (nurse practitioners and physician assistants)
Number of subjects: 9052
Study 28992721 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 202
Study 28992721 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cartilage implant
Number of subjects: 202
Study 28992721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 202
Study 26301086 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-Emotional Technique (NET)
Number of subjects: 90
Study 26301086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 24035770 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day regimen of antibiotics after catheter exchange
Number of subjects: 61
Study 24035770 — intervention group
Group type: COMPARATOR
Intervention: 10-day regimen of antibiotics with catheter retention
Number of subjects: 61
Study 21118681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50mg three times a day, titrated to 100mg three times a day after one month
Number of subjects: 96
Study 21118681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 21118681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose after 7 months of therapy
Number of subjects: 96
Study 20344882 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio Electric Asymmetric Treatment (REAC)
Number of subjects: 0
Study 20344882 — intervention group
Group type: COMPARATOR
Intervention: Es-Citalopram
Number of subjects: 0
Study 18157200 — intervention group
Group type: COMPARATOR
Intervention: Ventolin
Number of subjects: 12
Study 18157200 — intervention group
Group type: COMPARATOR
Intervention: Salamol (new)
Number of subjects: 12
Study 18157200 — intervention group
Group type: COMPARATOR
Intervention: Salamol (used)
Number of subjects: 12
Study 18157200 — intervention group
Group type: EXPERIMENTAL
Intervention: All inhalers (Ventolin, Salamol new, Salamol used)
Number of subjects: 12
Study 15628696 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg sKET
Number of subjects: 8
Study 15628696 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sKET
Number of subjects: 8
Study 15628696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11166983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant pictures
Number of subjects: 104
Study 11166983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant pictures with pain-related material
Number of subjects: 104
Study 11166983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant pictures without pain-related material
Number of subjects: 104
Study 11166983 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral pictures
Number of subjects: 104
Study 11270028 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1
Number of subjects: 35
Study 11270028 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 1 mg kg‐1
Number of subjects: 35
Study 9298432 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-focused training
Number of subjects: 29
Study 9298432 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused training
Number of subjects: 29
Study 9298432 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 29
Study 8348281 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 5 mg
Number of subjects: 0
Study 8348281 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) doses ranging from 5 to 20 mg
Number of subjects: 0
Study 3525169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sones or Gensini catheters (group A)
Number of subjects: 170
Study 3525169 — intervention group
Group type: COMPARATOR
Intervention: Pigtail catheters (group B)
Number of subjects: 170
Study 31420983 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized adaptive design
Number of subjects: 0
Study 31420983 — intervention group
Group type: COMPARATOR
Intervention: Optimized nonadaptive design
Number of subjects: 0
Study 30021711 — intervention group
Group type: EXPERIMENTAL
Intervention: ISG + cCBT
Number of subjects: 302
Study 30021711 — intervention group
Group type: COMPARATOR
Intervention: cCBT alone
Number of subjects: 302
Study 27421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down intervention (general health education and mHealth intervention)
Number of subjects: 60
Study 27421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (top-down intervention and peer education)
Number of subjects: 60
Study 27421881 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 60
Study 27421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down intervention
Number of subjects: 60
Study 27421881 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 60
Study 27421881 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 26021111 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen PVP
Number of subjects: 0
Study 26021111 — intervention group
Group type: COMPARATOR
Intervention: hylan GF-20
Number of subjects: 0
Study 23162576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel (A.V. 2% oral gel)
Number of subjects: 40
Study 23162576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 21197497 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted cemented restorations
Number of subjects: 44
Study 21197497 — intervention group
Group type: COMPARATOR
Intervention: Nonsplinted cemented restorations
Number of subjects: 44
Study 18543329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg orally twice a day for 28 days)
Number of subjects: 61
Study 18543329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15910187 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) + Pulsed Dye Laser (PDL)
Number of subjects: 24
Study 15910187 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 24
Study 15910187 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL) alone
Number of subjects: 24
Study 12627310 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) training group (n=10)
Number of subjects: 20
Study 12627310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Intensity (LO) training group (n=10)
Number of subjects: 20
Study 12627310 — intervention group
Group type: COMPARATOR
Intervention: Both HI and LO training groups
Number of subjects: 20
Study 10584468 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nursing care (mothers' group)
Number of subjects: 362
Study 10584468 — intervention group
Group type: COMPARATOR
Intervention: Professional nursing care (nurses' group)
Number of subjects: 362
Study 8917229 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Number of subjects: 24
Study 8917229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 24
Study 1872042 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbinac Gel 3% (1 g, three times daily)
Number of subjects: 281
Study 1872042 — intervention group
Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 281
Study 29103065 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (2 weekly sessions for 12 months)
Number of subjects: 116
Study 29103065 — intervention group
Group type: COMPARATOR
Intervention: Reference group (health-promoting lectures)
Number of subjects: 116
Study 25800784 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF monotherapy (300 mg/day)
Number of subjects: 102
Study 25800784 — intervention group
Group type: COMPARATOR
Intervention: TDF and ETV combination therapy (TDF 300 mg/day and ETV 1 mg/day)
Number of subjects: 102
Study 24827808 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² on days 21, 28, 35, 42, 175, 182, 189, and 196)
Number of subjects: 84
Study 24827808 — intervention group
Group type: COMPARATOR
Intervention: No rituximab
Number of subjects: 84
Study 24827808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 84
Study 22751980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anticoagulant-aspirin therapy (100-mg prophylactic dose)
Number of subjects: 213
Study 22751980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 213
Study 22751980 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy (100-mg prophylactic dose)
Number of subjects: 213
Study 20119899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprayed fibrin glue (study group)
Number of subjects: 10
Study 20119899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 10
Study 18309485 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 treatment
Number of subjects: 33
Study 17035614 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mEq of oral potassium citrate (Kcitrate)
Number of subjects: 161
Study 17035614 — intervention group
Group type: COMPARATOR
Intervention: 30 mEq of potassium chloride (KCl)
Number of subjects: 161
Study 17035614 — intervention group
Group type: COMPARATOR
Intervention: Both K supplements
Number of subjects: 161
Study 12784322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling schedules with 5%, 10%, or 50% of period 2 C(max) value added to observed concentrations.
Number of subjects: 0
Study 12784322 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with time 0 concentrations of 1%-10% of period 2 C(max) included or excluded in simulations.
Number of subjects: 0
Study 12784322 — intervention group
Group type: COMPARATOR
Intervention: True data with no carryover between periods.
Number of subjects: 0
Study 11085844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0